CYCLOTRONS AND POSITRON EMISSION TOMOGRAPHY RADIOPHARMACEUTICALS FOR CLINICAL IMAGING

被引:26
|
作者
SAHA, GB
MACINTYRE, WJ
GO, RT
机构
[1] Department of Nuclear Medicine, Cleveland Clinic Foundation, Cleveland, OH
关键词
D O I
10.1016/S0001-2998(05)80143-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Positron emission tomography (PET) requires positronemitting radionuclides that emit 511-keV photons detectable by PET imagers. Positron-emitting radionuclides are commonly produced in charged particle accelerators, eg, linear accelerators or cyclotrons. The most widely available radiopharmaceuticals for PET imaging are carbon-11-, nitrogen-13-, and oxygen-15-labeled compounds, many of which, either in their normal state or incorporated in other compounds, serve as physiological tracers. Other useful PET radiopharmaceuticals include fluorine-18-, bromine-75-, gallium-68 (68Ga)-, rubidium-82 (82Rb)-, and copper-62 (62Cu)-labeled compounds. Many positron emitters have short half-lives and thus require on-site cyclotrons for application, and others (68Ga, 82Rb, and 62Cu) are available from radionuclide generators using relatively long-lived parent radionuclides. This review is divided into two sections: cyclotrons and PET radiopharmaceuticals for clinical imaging. In the cyclotron section, the principle of operation of the cyclotron, types of cyclotrons, medical cyclotrons, and production of radionuclides are discussed. In the section on PET radiopharmaceuticals, the synthesis and clinical use of PET radiopharmaceuticals are described. © 1991 W.B. Saunders Company. All rights reserved.
引用
收藏
页码:150 / 161
页数:12
相关论文
共 50 条
  • [41] Newer positron emission tomography radiopharmaceuticals for radiotherapy planning: an overview
    Sharma, Punit
    Mukherjee, Anirban
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (03)
  • [42] Quality control of positron emission tomography radiopharmaceuticals: An institutional experience
    Shukla, Jaya
    Vatsa, Rakhee
    Garg, Nitasha
    Bhusari, Priya
    Watts, Ankit
    Mittal, Bhagwant R.
    INDIAN JOURNAL OF NUCLEAR MEDICINE, 2013, 28 (04): : 200 - 206
  • [43] Pharmacopoeial Quality Standards for Radiopharmaceuticals for Positron-Emission Tomography
    A. S. Gromakov
    E. I. Sakanyan
    S. P. Senchenko
    R. D. Ruziev
    Pharmaceutical Chemistry Journal, 2020, 54 : 419 - 421
  • [44] Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease
    Nagren, Kjell
    Halldin, Christer
    Rinne, Juha O.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (08) : 1575 - 1593
  • [45] Clinical Positron Emission Tomography/Magnetic Resonance Imaging Applications
    von Schulthess, Gustav K.
    Kuhn, Felix Pierre
    Kaufmann, Philipp
    Veit-Haibach, Patrick
    SEMINARS IN NUCLEAR MEDICINE, 2013, 43 (01) : 3 - 10
  • [46] THE CLINICAL ROLE OF METABOLIC IMAGING OF THE HEART BY POSITRON EMISSION TOMOGRAPHY
    SCHWAIGER, M
    HICKS, R
    JOURNAL OF NUCLEAR MEDICINE, 1991, 32 (04) : 565 - 578
  • [47] Radionuclides and radiopharmaceuticals for single-photon emission tomography, positron emission tomography and radiotherapy in Russia
    Krasikova, RN
    Kodina, GE
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (07) : 774 - 788
  • [48] Radionuclides and radiopharmaceuticals for single-photon emission tomography, positron emission tomography and radiotherapy in Russia
    Raisa N. Krasikova
    Galina E. Kodina
    European Journal of Nuclear Medicine, 1999, 26 : 774 - 788
  • [49] Positron Emission Tomography Imaging and Hyperinsulinism
    Hernandez-Pampaloni, Miguel
    Zhuang, Hongming
    Fanti, Stefano
    Alavi, Abass
    PET CLINICS, 2007, 2 (03) : 377 - +
  • [50] Positron emission tomography as an imaging biomarker
    Weber, Wolfgang A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (20) : 3282 - 3292